Redeye comments on Cinclus’ announcement that the first patient has been screened in its pivotal Phase III study with linaprazan glurate in erosive GERD. We view this as an important milestone that marks Cinclus’ transition into late-stage clinical development and sets the stage for what could be the most significant value-driving catalyst yet when topline results are reported in H2 2026e.
LÄS MER
